

Scientific Program and Conference Schedule

Saturday, October 19

Saturday, October 19

3:00 p.m.-4:30 p.m.

Educational Session 1: Cancer Genomics

Veterans Memorial Auditorium

Co-Chairpersons: Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA, USA, and **P. Andrew Futreal**, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Somatic alterations in human cancer genomes*

Matthew L. Meyerson

Challenges and opportunities for genomic medicine

P. Andrew Futreal

Advances and future of finding cancer-associated genes

Gad Getz, Broad Institute of MIT and Harvard, Cambridge, MA, USA, and Massachusetts General Hospital, Boston, MA, USA

4:30 p.m.-4:45 p.m.

Break

Boylston Street Hallway

4:45 p.m.-6:15 p.m.

Educational Session 2: PI3K and MEK Pathway Inhibitors

Veterans Memorial Auditorium

Co-Chairpersons: Lewis C. Cantley, Weill Cornell Medical College of Cornell University, New York, NY, USA, and **Richard M. Marais**, Cancer Research UK Manchester Institute, Manchester, United Kingdom

BRAF and RAS signaling in melanoma: From basic biology to clinical exploitation

Richard M. Marais

Title to be announced

Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Matrix-dependent adaptive resistance to targeted therapy

Joan S. Brugge, Harvard Medical School, Boston, MA, USA

6:30 p.m.-8:00 p.m.

Networking Reception

Sheraton Boston Hotel,
Grand Ballroom

Sunday, October 20

8:00 a.m.-10:05 a.m.

Opening Plenary Session: Opening Remarks and Keynote Lectures

Veterans Memorial Auditorium

Welcome and Opening Remarks

Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA, USA

Lee J. Helman, National Cancer Institute, Bethesda, MD, USA

Roger Stupp, University Hospital Zurich, Zurich, Switzerland

Keynote Lectures

Chairperson: Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA, USA

Wnt signaling, Lgr5 stem cells, and cancer*

Hans Clevers, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Centre, Utrecht, The Netherlands

Targeting the PD-1 pathway: Resetting the balance between the immune system and cancer

Suzanne L. Topalian, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

10:05 a.m.-10:30 a.m.

Break

Boylston Street Hallway

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

**10:30 a.m.-12:30 p.m. Plenary Session 1:
Latest Advances to
Overcome Resistance to
Targeted Therapies**
Veterans Memorial Auditorium

Co-Chairpersons: René Bernards, Netherlands Cancer Institute, Amsterdam, The Netherlands, and **Alice T. Shaw**, Massachusetts General Hospital Cancer Center, Boston, MA, USA

Using synthetic lethality to find effective combination therapies for cancer*

René Bernards

Mechanisms of resistance to RAF/MEK inhibitors

David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Overcoming acquired resistance to first-generation kinase inhibitors in lung cancer

William Pao, Vanderbilt University, Nashville, TN, USA

Mechanisms of acquired resistance to ALK/ROS1 inhibitors*

Alice T. Shaw

12:30 p.m.-3:00 p.m. Poster Session A
(not eligible for CME credit)
Exhibit Hall C-D

Angiogenesis and Antiangiogenesis Agents 1

Animal Models 1

Apoptosis, Necrosis, and Autophagy 1

Bioinformatics

Biomarkers 1

Cancer Stem Cells 1

Cellular Responses to Therapy 1

Clinical Trials 1

Drug Delivery

Drug Resistance and Modifiers 1

Drug Screening 1

EGFR/Her2 1

Epigenetic Targets

Genomics, Proteomics, and Target Discovery 1

In Vitro and In Vivo Models for Targets

Metastasis and Invasion 1

mTOR/PI3-Kinase 1

Natural Products

New Molecular Targets 1

Novel Assay Technology 1

Pharmacogenetics, Pharmacogenomics, and
Therapeutic Response

Pharmacokinetics and Pharmacodynamics 1

Signal Transduction Modulators

Target Identification and Validation 1

Therapeutic Agents: Biological 1

Therapeutic Agents: Other 1

Therapeutic Agents: Small Molecule Kinase Inhibitors 1

Tubulin-Interacting Agents

12:30 p.m.-3:00 p.m. Exhibit Show
Exhibit Hall C-D

**3:15 p.m.-5:15 p.m. Plenary Session 2: Targeting the
Metabolic Basis of Cancer**
Veterans Memorial Auditorium

Co-Chairpersons: Eyal Gottlieb, The Beatson Institute for Cancer Research, Glasgow, United Kingdom, and **Craig B. Thompson**, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

The metabolic phase of the cell cycle*

Eyal Gottlieb

The genetic basis of kidney cancer: A metabolic disease*

W. Marston Linehan, National Cancer Institute, Bethesda, MD, USA

Ras-induced macropinocytosis: Metabolic adaptation to signaling in the absence of adequate nutrients*

Craig B. Thompson

Targeting IDH mutations in cancer*

Katharine Yen, Agios Pharmaceuticals, Cambridge, MA, USA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

Scientific Program and Conference Schedule

Sunday, October 20

5:30 p.m.-6:30 p.m.

Proffered Paper Session 1

Veterans Memorial Auditorium

Chairperson: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA

PR01 Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange**

Michael Burns, Vanderbilt University School of Medicine, Nashville, TN, USA

PR02 LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6—Reactivating Rb in cancer**

Sunky Kim, Novartis Institutes for BioMedical Research, Cambridge, MA, USA

PR03 Selective sensitization of mutant K-Ras cancer cells to DNA damage-based therapies by targeting wild type H- and N-Ras**

Elda Grabocka, NYU Langone Medical Center, New York, NY, USA

PR04 BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition**

Katherine Hutchinson, Vanderbilt University, Nashville, TN, USA

6:30 p.m.-7:30 p.m.

Poster Session A (continued)

(not eligible for CME credit)

Exhibit Hall C-D

6:30 p.m.-7:30 p.m.

Exhibit Show (continued)

Exhibit Hall C-D

8:00 p.m.-10:00 p.m.

AACR Women in Cancer Research (WICR) Career Mentoring Session

Organized by the AACR Women in Cancer Research Council

(not eligible for CME credit)

Sheraton Boston Hotel, Fairfax Room

Co-Chairpersons: Jessie English, Dana-Farber Cancer Institute, Boston, MA, USA; **Wen-Jen Hwu**, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; **Victoria Richon**, Sanofi Oncology, Cambridge, MA, USA; and **Lillian Siu**, University Health Network Princess Margaret Hospital, Toronto, ON, Canada

This session has been designed for graduate students, medical students and residents, and clinical and postdoctoral fellows. Although all conference attendees are invited to attend this session, it is geared toward early-career female investigators. Advance registration was encouraged and onsite registration will be available on a first-come, first-served basis. Seating is limited.

Following a keynote address by Kornelia Polyak, M.D., Ph.D., attendees will meet, network, and learn from leading senior scientists in cancer research. Please join us! (A reception with food and drink is included.)

Keynote Address: Dream, Dare, Succeed

Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA, USA

Featured Mentors:

Careers in Academia

James E. Bradner, Dana-Farber Cancer Institute, Boston, MA, USA

Careers in Industry

Pamela Carroll, Janssen, Pharmaceutical Companies of Johnson & Johnson, Cambridge, MA, USA

**An extended abstract for this presentation is available in the Proffered Papers section of the *Proceedings*.

Writing a CV

Simone Fulda, J.W. Goethe University of Frankfurt, Frankfurt, Germany

Clinical Translational Research Careers for Early-Career Scientists

Judy Garber, Dana-Farber Cancer Institute, Boston, MA, USA

Oral Presentations

Lee J. Helman, National Cancer Institute, Bethesda, MD, USA

Translational Cancer Research for Basic Scientists

W. Marston Linehan, National Cancer Institute, Bethesda, MD, USA

A Career in Drug Discovery

Jeanette M. Wood, AstraZeneca, Macclesfield, Cheshire, United Kingdom

Monday, October 21

8:00 a.m.-10:00 a.m. **Plenary Session 3:
Epigenetic Regulators as
Therapeutic Targets**
Veterans Memorial Auditorium

Co-Chairpersons: James E. Bradner, Dana-Farber Cancer Institute, Boston, MA, USA, and **Chas Bountra**, University of Oxford, Headington, United Kingdom

Working together to identify new epigenetic targets for cancer*

Chas Bountra

Targeting enhancers in cancers

James E. Bradner

Designing p300/CBP histone acetyltransferase inhibitors for cancer*

Philip A. Cole, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Protein methyltransferase inhibitors as personalized cancer therapeutics*

Robert A. Copeland, Epizyme, Inc., Cambridge, MA, USA

10:00 a.m.-10:30 a.m. **Break**
Boylston Street Hallway

10:30 a.m.-12:30 p.m. **Plenary Session 4: Targeting
KRAS Mutant Cancers**
Veterans Memorial Auditorium

Co-Chairpersons: Julian Downward, Cancer Research UK, London, United Kingdom, and **Kevan M. Shokat**, University of California, San Francisco, CA, USA

Developing therapies for Ras-driven cancers*

Karen Cichowski, Brigham and Women's Hospital, Boston, MA, USA

Targeting MEK in KRAS mutant lung cancer*

Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

Direct targeting of mutant Ras proteins

Kevan M. Shokat

Synthetic lethal approaches to targeting Ras mutant cancers*

Julian Downward

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

Scientific Program and Conference Schedule

Monday, October 21

12:30 p.m.-3:00 p.m. **Poster Session B**
(not eligible for CME credit)
Exhibit Hall C-D

Angiogenesis and Antiangiogenesis Agents 2
Animal Models 2
Apoptosis, Necrosis, and Autophagy 2
Biomarkers 2
Cancer Stem Cells 2
Cell Cycle Regulators
Cellular Responses to Therapy 2
Clinical Trials 2
DNA Repair and Modulation 1
Drug Design
Drug Resistance and Modifiers 2
EGFR/Her2 2
Gene Therapies
Genomics, Proteomics, and Target Discovery 2
Imaging
Metabolism 1
Metastasis and Invasion 2
Molecular Classification of Tumors
mTOR/PI3-Kinase 2
New Molecular Targets 2
Other
Pharmacokinetics and Pharmacodynamics 2
RNA and RNA-Based Technologies and Therapies
Target Identification and Validation 2
Therapeutic Agents: Biological 2
Therapeutic Agents: Other 2
Therapeutic Agents: Small Molecule Kinase Inhibitors 2
Tumor Immunology Targets

12:30 p.m.-3:00 p.m. **Exhibit Show**
Exhibit Hall C-D

3:15 p.m.-5:15 p.m. **Concurrent Session 1: RNAi
Therapeutics: Hype or Hope?**
Ballroom B

Co-Chairpersons: **Frank McCormick**, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA, and **Judy Lieberman**, Harvard Medical School, Boston, MA, USA

Opportunities for systemic treatment using siRNA in nanoparticles

Frank McCormick

Targeting basal-like TNBCs and epithelial tumor-initiating cells with aptamer-siRNA chimeras*

Judy Lieberman

Prospects for miRNA- and lncRNA-based cancer therapeutics*

Reuven Agami, Netherlands Cancer Institute, Amsterdam, The Netherlands

RNAi therapeutics in cancer: Clinical results with nanoparticle siRNA delivery systems

Jared Gollob, Alnylam Pharmaceuticals, Inc., Cambridge, MA, USA

3:15 p.m.-5:15 p.m. **Concurrent Session 2:
Molecular Diagnostics: Bringing
the Latest Technologies to
Clinical Development**
Ballroom A

Co-Chairpersons: **Jean-Charles Soria**, Institut Gustave-Roussy, Villejuif, France, and **Anthony John Iafrate**, Massachusetts General Hospital, Boston, MA, USA

CTCs in small cell lung cancer: Biomarkers and biology*

Caroline Dive, Cancer Research UK Manchester Institute, Manchester, United Kingdom

From precision medicine to personalized medicine in metastatic breast cancer patients*

Fabrice André, Institut Gustave-Roussy, Villejuif, France

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

Targeted multiplexed DNA sequencing for biomarker discovery and clinical diagnosis*

Michael F. Berger, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Title to be announced

Anthony John Iafrate

3:15 p.m.-5:15 p.m.

Concurrent Session 3: Novel Laboratory Models to Assess Cancer Therapeutics

Veterans Memorial Auditorium

Co-Chairpersons: William R. Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA, USA, and **Norman E. Sharpless**, The Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA

Drug testing in genetically engineered murine models*

Norman E. Sharpless

Conditionally reprogrammed cells for personalized medicine*

Richard Schlegel, Georgetown University School of Medicine, Washington, DC, USA

Use of the zebrafish for studying cancer genetics*

Leonard I. Zon, HHMI/Boston Children's Hospital, Boston, MA, USA

Towards robust and systematic translational systems for cancer therapeutic development

William R. Sellers

3:15 p.m.-5:15 p.m.

Concurrent Session 4: Targeting Apoptotic Regulators

Ballroom C

Co-Chairpersons: Anthony G. Letai, Dana-Farber Cancer Institute, Boston, MA, USA, and **Simone Fulda**, J. W. Goethe University of Frankfurt, Frankfurt, Germany

Poking cancer cells with BH3 profiling to personalize cancer therapy*

Anthony G. Letai

Discovery of Mcl-1 inhibitors using fragment-based methods*

Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, TN, USA

Modeling Myc as a therapeutic cancer target

Gerard I. Evan, University of Cambridge, Cambridge, United Kingdom

Targeting death receptors and SMAC mimetics*

Simone Fulda

5:30 p.m.-6:30 p.m.

Proffered Paper Session 2

Veterans Memorial Auditorium

Chairperson: Roger Stupp, University Hospital Zurich, Zurich, Switzerland

PR05 Resistance to Hedgehog inhibitor through Smoothed receptor mutation in basal cell carcinoma**

Sabrina Pricl, University of Trieste, Trieste, Italy

PR06 A functional screen of the epigenome identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers**

Zainab Jagani, Novartis Institutes for BioMedical Research, Cambridge, MA, USA

PR07 Novel oncogenic mutations in the beta subunit of heteromeric G-proteins identified by functional cDNA library screening*

Akinori Yoda, Dana-Farber Cancer Institute, Boston, MA, USA

PR08 Loss of oncogenic Notch1 signaling contributes to PI3 kinase inhibitor resistance in T lineage leukemia**

Monique Dail, University of California, San Francisco, CA, USA

6:30 p.m.-7:30 p.m.

Poster Session B (continued)

(not eligible for CME credit)

Exhibit Hall C-D

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

**An extended abstract for this presentation is available in the Proffered Papers section of the *Proceedings*.

Scientific Program and Conference Schedule

Monday, October 21

6:30 p.m.-7:30 p.m.

Exhibit Show (continued)
Exhibit Hall C-D

Mathematical modeling of tumor heterogeneity
Franziska Michor, Dana-Farber Cancer Institute, Boston, MA, USA

7:30 p.m.-9:00 p.m.

AACR Chemistry in Cancer Research (CICR) Working Group Town Hall
(not eligible for CME credit)
Sheraton Boston Hotel, Commonwealth Room

Phylogenetic quantification of intratumor heterogeneity predicts time to relapse in high-grade serous ovarian cancer*
Florian Markowitz, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom

Temporal evaluation of cancer heterogeneity*
Elaine R. Mardis

Chairperson: Michael J. Luzzio, Novartis Institutes for BioMedical Research, Cambridge, MA, USA

The Chemistry in Cancer Research (CICR) Working Group brings together cancer-focused scientists in chemistry and chemistry-related fields to discuss the present status and future promise of chemistry in the advancement of the prevention and cure of cancer. All CICR members are encouraged to attend and all interested Conference registrants are also invited. This event will provide an opportunity to meet with Dr. Michael J. Luzzio, CICR Steering Committee Chair, raise questions, and contribute ideas to help shape future CICR initiatives. Attendees can also learn about membership in CICR, meet the members of the Steering Committee, and connect with colleagues. A networking reception will follow.

10:00 a.m.-10:30 a.m.

Break
Boylston Street Hallway

10:30 a.m.-12:30 p.m.

Plenary Session 6: CTCs: Noninvasive Monitoring of Cancers
Veterans Memorial Auditorium

Co-Chairpersons: Daniel A. Haber, Massachusetts General Hospital, Charlestown, MA, USA, and **Alberto Bardelli**, IRCC - University of Turin, Medical School, Candiolo, Italy

Liquid biopsies to monitor response and resistance to targeted therapies*

Alberto Bardelli

Cancer exomes in plasma to track clonal evolution and resistance

Carlos M. Caldas, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing*

Mark Sausen, Personal Genome Diagnostics, Baltimore, MD, USA

Molecular characterization of circulating tumor cells*
Daniel A. Haber

Tuesday, October 22

8:00 a.m.-10:00 a.m.

Plenary Session 5: Genomic Heterogeneity in Cancers: Implications for Responsiveness
Veterans Memorial Auditorium

Co-Chairpersons: Elaine R. Mardis, Washington University School of Medicine, Saint Louis, MO, USA, and **Kornelia Polyak**, Dana-Farber Cancer Institute, Boston, MA, USA

Heterogeneity in DCIS and invasive breast cancers*

Kornelia Polyak

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

12:30 p.m.-3:00 p.m. Poster Session C
(not eligible for CME credit)
Exhibit Hall C-D

Angiogenesis and Antiangiogenesis Agents 3
Animal Models 3
Apoptosis, Necrosis, and Autophagy 3
Biomarkers 3
Cellular Responses to Therapy 3
Chemistry
Chemoprevention
Clinical Trials 3
DNA Repair and Modulation 2
Drug Metabolism, Transport, and Biodistribution
Drug Resistance and Modifiers 3
Drug Screening 2
EGFR/Her2 3
Genomics, Proteomics, and Target Discovery 3
Heat Shock Proteins
Hormonal Agents and Therapy
MAPK Pathways
Metabolism 2
Monoclonal Antibodies
mTOR/PI3-Kinase 3
New Molecular Targets 3
Novel Assay Technology 2
Pediatric-Early Drug Development
Protein-Protein Interaction
Radiotherapeutics
Target Identification and Validation 3
Therapeutic Agents: Biological 3
Therapeutic Agents: Other 3
Therapeutic Agents: Small Molecule Kinase Inhibitors 3
Topoisomerase Inhibitors
Toxicology
Tumor Microenvironment
Tumor Suppressors

12:30 p.m.-3:00 p.m. Exhibit Show
Exhibit Hall C-D

3:15 p.m.-5:15 p.m. Concurrent Session 5: Back to the Future: Targeting Cell Cycle and DNA Repair
Ballroom C

Co-Chairpersons: Alan D. D'Andrea, Dana-Farber Cancer Institute, Boston, MA, USA, and **Yves G. Pommier**, National Cancer Institute, Bethesda, MD, USA

PARP inhibitors: Trapping of PARP and rationale for combinations*
Yves G. Pommier

Targeting the Fanconi anemia/BRCA pathway*
Alan D. D'Andrea

Targeting oncogene-induced DNA damage for cancer therapy*
Oscar Fernandez-Capetillo, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

Novel DNA repair targets for anticancer treatments*
Thomas Helleday, Karolinska Institute, Stockholm, Sweden

3:15 p.m.-5:15 p.m. Concurrent Session 6: EMT, Cellular Plasticity, Cellular Differentiation, and Response to Therapies
Ballroom B

Co-Chairpersons: Jeffrey E. Settleman, Genentech, Inc., South San Francisco, CA, USA, and **Robert A. Weinberg**, MIT Whitehead Institute for Biomedical Research, Cambridge, MA, USA

Cancer stem cells and the EMT*
Robert A. Weinberg

Breast cancer stem cells*
Jenny C. Chang, Methodist Cancer Center, The Methodist Hospital, Houston, TX, USA

Cell plasticity promotes drug resistance and pathway redundancy*

John D. Haley, Network Pharmacology LLC, Sea Cliff, NY, USA

Reversible tolerance to anticancer drugs*
Jeffrey E. Settleman

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

**An extended abstract for this presentation is available in the Proffered Papers section of the *Proceedings*.

Scientific Program and Conference Schedule

Tuesday, October 22

3:15 p.m.-5:15 p.m.

Concurrent Session 7: Developing Combination Therapy Approaches in the Lab and Clinic

Veterans Memorial Auditorium

Co-Chairpersons: José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, and **Jeffrey A.**

Engelman, Massachusetts General Hospital, Charlestown, MA, USA

Monitoring downstream responses to MAP kinase pathway inhibitor therapy in BRAF mutant melanoma to support rational combinations strategies*

Keith Thomas Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA, USA

Novel combinations for KRAS and PIK3CA mutant cancers

Jeffrey A. Engelman

Rationale for combined PI3K and mTOR blockade

José Baselga

Title to be announced

James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

3:15 p.m.-5:15 p.m.

Concurrent Session 8: Using Genomics From Cell Line Screens to Inform Drug Development

Ballroom A

Co-Chairpersons: Mathew Garnett, Wellcome Trust Sanger Institute, Cambridge, United Kingdom, and **Levi A.**

Garraway, Dana-Farber Cancer Institute, Boston, MA, USA

Title to be announced

Levi A. Garraway

Therapeutic biomarker discovery in cancer cells*

Mathew Garnett

Synthetic lethal screens using RNAi*

Christopher Lord, Institute of Cancer Research, London, United Kingdom

Integrative genomics approaches to find targets and their combinations

Dana Pe'er, Columbia University, New York, NY, USA

5:30 p.m.-6:30 p.m.

Proffered Paper Session 3

Veterans Memorial Auditorium

Chairperson: Lee J. Helman, National Cancer Institute, Bethesda, MD, USA

PR09 Synergistic activity of CRLX101, a nanopharmaceutical in phase II clinical trials, with antiangiogenic therapies mediated through HIF-1alpha inhibition: A translational research program**

Scott Eliasof, Cerulean Pharma Inc., Cambridge, MA, USA

PR10 Is CNS availability for oncology a no-brainer?

Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations**

Ted W. Johnson, Pfizer, Inc., San Diego, CA, USA

PR11 Use of a DNA damage multiplex immunofluorescence assay to monitor pharmacodynamic markers following in vitro exposure to therapeutic agents**

Allison M. Marrero, SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick, MD, USA

PR12 MLN0264, an investigational, first-in-class antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC), demonstrates antitumor activity alone and in combination with gemcitabine in human pancreatic cancer xenograft models expressing GCC**

Julie Zhang, Millennium: the Takeda Oncology Company, Cambridge, MA, USA

6:30 p.m.-7:30 p.m.

Poster Session C (continued)

(not eligible for CME credit)

Exhibit Hall C-D

6:30 p.m.-7:30 p.m.

Exhibit Show (continued)

Exhibit Hall C-D

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

**An extended abstract for this presentation is available in the Proffered Papers section of the *Proceedings*.

Wednesday, October 23

8:00 a.m.-10:00 a.m. **Plenary Session 7:
Immunotherapy**
Veterans Memorial Auditorium

Co-Chairpersons: Alexander M. Marie Eggermont,
Institute Gustave-Roussy and University Paris-Sud, Paris,
France, and **Carl H. June**, Abramson Cancer Center of the
University of Pennsylvania, Philadelphia, PA, USA

Immune checkpoint blockade in cancer therapy: New
insights and opportunities*

James P. Allison, The University of Texas MD Anderson
Cancer Center, Houston, TX, USA

The renaissance of immunotherapy*

Alexander M. Marie Eggermont

Mechanisms of protective tumor immunity*

Glenn Dranoff, Dana-Farber Cancer Institute, Boston, MA,
USA

Engineered T cell transfer for cancer immunotherapy in the
era of synthetic biology: Challenges and opportunities*

Carl H. June

*An extended abstract for this presentation is available in the
Invited Abstracts section of the Proceedings.

10:00 a.m.-10:30 a.m. **Break**
Boylston Street Hallway

10:30 a.m.-12:30 p.m. **Plenary Session 8: Combining
Immunotherapies, Immune
Modulators, and Targeted
Therapies: Regulatory
Opportunities and Challenges**
Veterans Memorial Auditorium

Moderator: F. Stephen Hodi, Dana-Farber Cancer Institute,
Boston, MA, USA

Introductions

F. Stephen Hodi

Title to be announced

Ke Liu, U.S. Food and Drug Administration-CBER, Rockville,
MD, USA

Title to be announced

Michael A. Postow, Memorial Sloan-Kettering Cancer
Center, New York, NY, USA

Title to be announced

Renzo Canetta, Bristol-Myers Squibb Co., Wallingford, CT,
USA

Title to be announced

Louise M. Perkins, Melanoma Research Foundation,
Washington, DC, USA

Panel Discussion/Q & A with audience

12:30 p.m.-12:45 p.m. **Closing Remarks**
Veterans Memorial Auditorium

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.